Search results

15 results for Zoledronic acid

Sorted by Relevance . Sort by Date

  1. Myeloma: diagnosis and management (NG35)

    This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

  2. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults

  3. Osteoporosis

    Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

  4. Multimorbidity

    Everything NICE has said on optimising care for people with 2 or more long-term health conditions in an interactive flowchart

  5. Medicines optimisation

    Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart

  6. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  7. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  8. Early and locally advanced breast cancer

    Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

  9. Block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

  10. Prostate cancer

    Everything NICE has said on diagnosing and treating prostate cancer in an interactive flowchart

  11. Research recommendations

    CG155/2 | What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and young people considered...